Patents by Inventor Xiao-Jun Ma
Xiao-Jun Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090270271Abstract: The invention provides materials and methods for the detection of nucleic acid expression via the 3? portion of expressed sequences. Embodiments of the invention include the use of microarrays comprising nucleic acid probes that are complementary to the 3? end of expressed sequences and by the use of quantitative PCR (Q-PCR) based amplification of sequences found at or near the 3? end of expressed sequences. The invention may be used to detect the presence of expressed nucleic acids encoding particular gene products (sequences present in a “transcriptome”).Type: ApplicationFiled: September 15, 2008Publication date: October 29, 2009Inventors: Mark G. Erlander, Xiao-Jun Ma, Thomas Baer
-
Publication number: 20090215037Abstract: This invention relates to the identification and use of a subset of transcribed genes, wherein the expression of genes in the subset are able to classify cells among a plurality of classes. Methods for the identification or selection of such subsets are provided, along with computer implemented means for the application of the methods. The invention further provides physical embodiments based on the gene sequences of the subsets as well as methods for the use of the identified sets of gene sequences to classify a cell or tissue sample.Type: ApplicationFiled: February 16, 2006Publication date: August 27, 2009Applicant: AviaraDx, Inc.Inventors: Xiao-Jun Ma, Xianqun Wang, Mark G. Erlander
-
Publication number: 20090092973Abstract: Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.Type: ApplicationFiled: November 28, 2007Publication date: April 9, 2009Applicants: AVIARADX, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
-
Patent number: 7504214Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: GrantFiled: December 2, 2003Date of Patent: March 17, 2009Assignee: bioTheranostics, Inc.Inventors: Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi
-
Publication number: 20090059865Abstract: The present invention provides a communication system for performing the seamless handover of a mobile station between at least a first wireless access point and a second wireless access point within wireless LAN. The mobile station is in the coverage of at least the first wireless access point for receiving and/or sending the data from and/or to the first wireless access point. The system comprises a first server for storing data from a data source; a switch for exchanging the data between the first server and the first and second wireless access points; and a second server coupled to the switch, for receiving the data from the first server via a switch when the mobile station roams from one access point to another one, and transferring the stored data to the mobile station through the switch after the roaming.Type: ApplicationFiled: February 14, 2007Publication date: March 5, 2009Inventors: Huan Qiang Zhang, Xiao Jun Ma, Jun Li, Chuanming Wang
-
Publication number: 20070020655Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: June 2, 2006Publication date: January 25, 2007Applicant: AviaraDx, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20060286579Abstract: This invention provides gene sequence identities and methods for the determination of cellular gene expression and the comparison of expression levels between different gene sequences and between different cells. The gene sequences may be used as reference, normalization, or “housekeeping” gene sequences, the expression of which remains consistent in individual cells, even under different conditions, as well as among cells from different samples and origins.Type: ApplicationFiled: June 2, 2006Publication date: December 21, 2006Applicant: AviaraDx, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20060263806Abstract: Methods and compositions are provided for the detection of breast cancer based upon the identification of three biomarkers for non-normal breast cells. The biomarkers were identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer. Two biomarkers display increased expression in non-normal cells while the third biomarker displays decreased expression in non-normal cells.Type: ApplicationFiled: May 2, 2006Publication date: November 23, 2006Applicant: AviaraDx, Inc.Inventors: Xiao-Jun Ma, Dennis Sgroi, Mark Erlander
-
Publication number: 20060154267Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.Type: ApplicationFiled: March 24, 2005Publication date: July 13, 2006Applicant: Arcturus Bioscience, Inc.Inventors: Xiao-Jun Ma, Mark Erlander, Dennis Sgroi, Edward Enright
-
Publication number: 20060094035Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: June 3, 2005Publication date: May 4, 2006Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20060088851Abstract: This invention relates to the detection of increased expression from the HoxB13 (homeobox B13) gene as indicative of an invasive or metastatic cancer phenotype. The invention provides methods of detecting the level of expression from the HoxB13 gene, optionally in combination with nodal status, as an indicator of the invasive or metastatic phenotype as well as increased cellular migration and/or mobility. The invention also provides for the measurement of expression from the HoxB13 gene to assist in the determination of patient prognosis as well as clinical diagnosis and treatment.Type: ApplicationFiled: June 3, 2005Publication date: April 27, 2006Applicants: Arcturus Bioscience, Inc., General Hospital CorporationInventors: Mark Erlander, Dennis Sgroi, Xiao-Jun Ma
-
Publication number: 20050255481Abstract: The invention relates to the identification and use of sequences from expressed progesterone receptor transcripts in relation to breast cancer. In particular, the invention provides the identities of polynucleotide sequences that may be used to identify populations that are positive for estrogen receptor expression. The expressed polynucleotide sequences may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient.Type: ApplicationFiled: May 11, 2004Publication date: November 17, 2005Inventors: Xiao-Jun Ma, Edward Enright, Mark Erlander
-
Publication number: 20050239079Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: ApplicationFiled: December 2, 2003Publication date: October 27, 2005Applicant: Arcturus Engineering, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Dennis Sgroi
-
Publication number: 20050239083Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: ApplicationFiled: February 6, 2004Publication date: October 27, 2005Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Dennis Sgroi
-
Publication number: 20050208500Abstract: The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of populations that are positive and negative for estrogen receptor expression. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient, including breast cancer survival.Type: ApplicationFiled: March 4, 2004Publication date: September 22, 2005Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
-
Publication number: 20050100933Abstract: The invention provides for the identification and use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the invention provides the identities of genes that are correlated with patient survival and breast cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with breast cancer and to predict breast cancer recurrence and. The profiles may also be used in the study and/or diagnosis of breast cancer cells and tissue, including the grading of invasive breast cancer, as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of breast cancer based upon the likelihood of life expectancy and recurrence.Type: ApplicationFiled: June 18, 2004Publication date: May 12, 2005Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
-
Publication number: 20050095607Abstract: The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast cancer patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast cancer survival.Type: ApplicationFiled: March 5, 2004Publication date: May 5, 2005Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
-
Publication number: 20050014168Abstract: The invention provides materials and methods for the detection of nucleic acid expression via the 3? portion of expressed sequences. Embodiments of the invention include the use of microarrays comprising nucleic acid probes that are complementary to the 3? end of expressed sequences and by the use of quantitative PCR (Q-PCR) based amplification of sequences found at or near the 3? end of expressed sequences. The invention may be used to detect the presence of expressed nucleic acids encoding particular gene products (sequences present in a “transcriptome”).Type: ApplicationFiled: January 30, 2004Publication date: January 20, 2005Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Thomas Baer
-
Publication number: 20050009047Abstract: The present invention provides methods for the amplification of nucleic acid molecules. Methods for amplifying target polynucleotides, including mRNA, using oligonucleotides, DNA and RNA polymerases are provided. The invention further provides compositions and kits for practicing the methods, as well as methods which use the amplification products.Type: ApplicationFiled: March 19, 2004Publication date: January 13, 2005Inventors: Mark Erlander, Ranelle Salunga, Xiao-Jun Ma, Eddy Enright
-
Publication number: 20040002084Abstract: This invention relates to the immune response activity of eosinophils, and especially activated eosinophils, and provides isolated nucleic acids, polypeptides, including fragments, subunits and variants of the nucleic acids and polypeptides, as well as related compositions, probes, vectors, host cells, antibodies, and methods. In one aspect, the invention provides isolated nucleic acids encoding specific eosinophil-derived polypeptides or fragments or variants. Generally, the nucleic acids comprise a sequence encoding at least one domain or region associated with an eosinophil biochemical pathway function or associated with activated eosinophils. And, generally, corresponding domains or regions of polypeptides of the invention have at least a five amino acid fragment encoded by one of SEQ NOS: 1-71.Type: ApplicationFiled: January 24, 2003Publication date: January 1, 2004Inventors: Stanton B. Dotson, Xiao Jun Ma